Delphine Rea

Delphine Rea

UNVERIFIED PROFILE

Are you Delphine Rea?   Register this Author

Register author
Delphine Rea

Delphine Rea

Publications by authors named "Delphine Rea"

Are you Delphine Rea?   Register this Author

85Publications

3105Reads

26Profile Views

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.

Curr Hematol Malig Rep 2019 Dec;14(6):492-500

Service d'Hématologie Adultes, Hôpital Saint-Louis, APHP, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00546-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934631PMC
December 2019

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.

Am J Hematol 2019 03 25;94(3):346-357. Epub 2018 Nov 25.

Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25342
Publisher Site
http://dx.doi.org/10.1002/ajh.25342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587857PMC
March 2019

[NK cells: a major role in the antitumoral immunomodulation in CML].

Med Sci (Paris) 2018 Jun-Jul;34(6-7):540-546. Epub 2018 Jul 31.

Inserm UMR 1160, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France - France intergroupe des leucémies myéloïdes chroniques (Fi-LMC), Institut Bergonié, 33000 Bordeaux, France - Service d'hématologie adulte, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France.

View Article

Download full-text PDF

Source
https://www.medecinesciences.org/10.1051/medsci/20183406013
Publisher Site
http://dx.doi.org/10.1051/medsci/20183406013DOI Listing
January 2019

Eruptive melanocytic nevi associated with ponatinib.

JAAD Case Rep 2018 Nov 12;4(10):1052-1054. Epub 2018 Nov 12.

Service de Dermatologie, CHU Amiens Picardie, Amiens, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.07.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234612PMC
November 2018

Treatment-free remission in patients with chronic myeloid leukemia.

Int J Hematol 2018 Oct 8;108(4):355-364. Epub 2017 Jul 8.

Laboratoire Central d'Hématologie, EA3518 Université Paris 7 and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-017-2295-0DOI Listing
October 2018

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

Am J Hematol 2018 10 31;93(10):E342-E345. Epub 2018 Aug 31.

Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25232DOI Listing
October 2018

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.

Br J Haematol 2018 01 19;180(1):24-32. Epub 2017 Oct 19.

Unicancer Center, Institut Bergonié and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Bordeaux, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.14973
Publisher Site
http://dx.doi.org/10.1111/bjh.14973DOI Listing
January 2018

What is treatment free remission in chronic myeloid leukemia?

Oncotarget 2018 Jan 18;9(4):4279. Epub 2017 Dec 18.

Institut Bergonie Cancer Center, Department of Hematology, Universite Bordeaux, Bordeaux, Aquitaine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796972PMC
January 2018

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.

Crit Rev Oncol Hematol 2017 Dec 8;120:52-59. Epub 2017 Oct 8.

Department of Hematology and Oncology "L. and A. Seràgnoli," St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428173006
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2017.10.002DOI Listing
December 2017

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Leuk Res 2017 09 26;60:94-102. Epub 2017 Jul 26.

INSERM, U935, F-86000 Poitiers, France; Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France; NSERM U935, F-94807 Villejuif, France; Université Paris Sud, F-94270 Le Kremlin-Bicêtre, France; Hôpital Bicêtre, Service d'Hématologie Biologique, F-94270 Le Kremlin Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.07.007DOI Listing
September 2017

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

J Clin Oncol 2017 Jan 31;35(3):298-305. Epub 2016 Oct 31.

Gabriel Etienne and François-Xavier Mahon, Institut Bergonié, Bordeaux; Joëlle Guilhot and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers; Delphine Rea, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP); Bruno Varet, Hôpital Necker, AP-HP et Université Paris Descartes, Paris; Françoise Rigal-Huguet, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse; Franck Nicolini, Centre Hospitalier Lyon Sud, Pierre Bénite; Aude Charbonnier, Institut Paoli Calmette, Marseille; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Laurence Legros, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice; Martine Gardembas, CHU d'Angers, Angers; Viviane Dubruille, CHU Hôtel-Dieu, Nantes; Michel Tulliez, Hôpital Henri Mondor, Créteil; Marie-Pierre Noel, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille; Jean-Christophe Ianotto, CHU Morvan, Brest; Bruno Villemagne, Centre Hospitalier Départemental La Roche-Sur-Yon, La Roche-Sur-Yon; Martin Carré, Hôpital Albert Michallon, CHU de Grenoble, Grenoble; Philippe Rousselot, Hôpital André Mignot, Le Chesnay; and François-Xavier Mahon, CHU de Bordeaux, INSERM U1218, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2914DOI Listing
January 2017

Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.

J Invest Dermatol 2016 06 15;136(6):1302-1305. Epub 2016 Feb 15.

INSERM U976 and Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2015.12.047DOI Listing
June 2016

Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2016 Mar 20;16(3):169-74. Epub 2015 Dec 20.

Department of Renal Physiology, DHU Fire, Bichat Hospital, AP-HP, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM, U1149, Centre de Recherche sur l'Inflammation, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.12.001DOI Listing
March 2016

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.

Am J Hematol 2015 Nov 12;90(11):1060-4. Epub 2015 Oct 12.

Scottish Pulmonary Vascular Unit, Glasgow, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24174DOI Listing
November 2015

Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.

Eur J Haematol 2015 Apr 23;94(4):363-7. Epub 2014 Aug 23.

Médecine Vasculaire, Hôpital Européen Georges-Pompidou, AP-HP, Paris, France; Sorbonne Paris Cité, Université Paris Descartes, Paris, France; INSERM U970, PARCC, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12367DOI Listing
April 2015

Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:
Delphine Rea

Ann Hematol 2015 Apr 27;94 Suppl 2:S149-58. Epub 2015 Mar 27.

Service d'Hématologie Adulte, Hôpital Saint-Louis, AP-HP, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10, France,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-015-2318-y
Publisher Site
http://dx.doi.org/10.1007/s00277-015-2318-yDOI Listing
April 2015

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

Blood 2015 Feb 18;125(6):901-6. Epub 2014 Dec 18.

Medical Clinic for Hematology and Oncology, Campus Virchow, Charité, Medical University of Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-594432DOI Listing
February 2015

Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.

Clin Biochem 2014 Sep 8;47(13-14):1333-6. Epub 2014 Jun 8.

Laboratory of Hematology, University Hospital Saint-Louis, AP-HP, Paris, France; EA3518, University Paris Diderot, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2014.05.067DOI Listing
September 2014

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J Clin Oncol 2014 Feb 9;32(5):424-30. Epub 2013 Dec 9.

Philippe Rousselot, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines, Versailles; Aude Charbonnier, Institut Paoli Calmette, Marseille; Pascale Cony-Makhoul, Hôpital d'Annecy, Pringy; Philippe Agape, Hôpital Felix Guyon-Centre Hospitalier Universitaire en France (CHU) de la Réunion, La Réunion; Franck E. Nicolini, Centre Hospitalier Lyon Sud, Pierre-Bénite; Bruno Varet, Hôpital Necker, Assistance Publique-Hopitaux de Paris (AP-HP) et Université Paris Descartes; Delphine Réa and Jean Michel Cayuela, Hôpital Saint-Louis, AP-HP, Paris; Martine Gardembas, CHU d'Angers, Angers; Gabriel Etienne and Josy Reiffers, Institut Bergonié; François-Xavier Mahon, Hôpital Haut-Levèque et Université Bordeaux Ségalen, Bordeaux; Lydia Roy, Joëlle Guilhot, and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM) Centres d'Investigation Clinique CHU de Poitiers, Poitiers; Martine Escoffre-Barbe, Centre Hospitalier Pontchaillou, Rennes; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Michel Tulliez, Hôpital Henri Mondor, AP-HP, Créteil; Stéphane Prost, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses; Marc Spentchian, Hôpital Mignot, Le Chesnay; and Jean Claude Chomel and Ali Turhan, INSERM U935, Université Poitiers et Paris Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5797DOI Listing
February 2014

Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.

Leuk Res 2012 Jul 23;36(7):817-25. Epub 2012 Feb 23.

Patient Reported Outcomes, Adelphi Values, Cheshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.01.021DOI Listing
July 2012

Curing chronic myeloid leukemia.

Curr Hematol Malig Rep 2012 Jun;7(2):103-8

Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, AP-HP, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-012-0117-2DOI Listing
June 2012

Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Am J Respir Crit Care Med 2007 Oct 28;176(8):814-8. Epub 2007 Jun 28.

Université Denis Diderot-Paris 7, Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Saint-Louis 1, Avenue Claude Vellefaux, 75475 Paris, Cedex 10, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.200705-715CRDOI Listing
October 2007

Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells.

Cell Microbiol 2007 Jun 23;9(6):1412-25. Epub 2007 Jan 23.

INSERM, U662, Institut Universitaire d'Hématologie, Université Paris VII, and Laboratoire d'Immunologie et d'Histocompatibilité, Centre d'Investigation Biomédicales, AP-HP, Hôpital Sait-Louis, Paris, F-75010, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1462-5822.2006.00881.xDOI Listing
June 2007

Quantification of nucleated red blood cells in allogeneic marrow graft and impact of processing on recovery.

Transfusion 2007 Feb;47(2):266-71

Cell Therapy Unit and the Bone Marrow Transplant Department, Public Assistance Hospitals of Paris, Saint-Louis Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1537-2995.2007.01099.xDOI Listing
February 2007

BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.

J Immunol 2006 Apr;176(8):5108-16

Institut National de la Santé et de la Recherche Médicale, Unité 622, Centre d'Investigations Biomédicales, Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.176.8.5108DOI Listing
April 2006

Adenoviral transduction of dendritic cells.

Methods Mol Med 2005 ;109:83-96

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-862-5:083DOI Listing
March 2005